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Introduction
Cell therapy for diabetes mellitus will be advanced by the 
availability  of  additional  donor  cells.  Islet  cells  may 
originate from pancreatic ductal or other epithelial cells, 
especially  after  damage  in  the  adult  pancreas  [1,  2]. 
However, the replication potential of human pancreatic 
islet cells is limited, which generally restricts expansion 
of these cells under culture conditions [3]. Although cell 
lines have been generated by oncogenetic transformation 
of  islet  cells  [4,  5]  tumorigenic  cells  will  obviously  be 
unsuitable  for  basic  studies  under  various  contexts,  as 
well as for cell therapy. This problem of genetic trans­
formation  afflicts  other  sources  of  cells,  for  example, 
inducible  pluripotential  stem  cells  (iPS),  which  are 
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medium, provided the original work is properly cited.teratogenic [6]. Whereas reprogramming of cells through 
transcription factor modifications was recently found to 
be  effective  for  transdifferentiating  pancreatic  exocrine 
cells to endocrine beta cells in vivo [7], generalization of 
this  observation  in  developing  treatments  for  diabetes 
mellitus requires much more work.
We consider fetal tissues to be of considerable interest 
as cell donors because these are particularly enriched in 
lineage­committed  stem/progenitor  cells.  However,  in 
comparison  with  pluripotent  human  embryonic  stem 
cells (hESC) or iPS, the replication potential of fetal cells 
was limited [8, 9], possibly due to telomere shortening [3, 
10].  Modification  of  fetal  human  liver  cells  with  the 
catalytic  subunit  of  human  telomerase  reverse  trans­
criptase (hTERT) enhanced cell replication without loss 
of  stem/progenitor  cell  properties  and  additional 
expression of pancreatic duodenal homeobox (Pdx)­1 in 
these cells induced regulated insulin expression [10, 11]. 
On the other hand, we recently determined that epithelial 
fetal human liver cells became altered under continuous 
culture,  with  development  of  a  novel  conjoint  meso­
endodermal phenotype under control of transcriptional 
regulation  mechanisms  [9].  As  nuclear  transcription 
factors  are  of  fundamental  significance  in  directing 
embry  onic development of the foregut endoderm, which 
originates both hepatic and pancreatic stem/progenitor 
cells [12], we considered that pancreatic fetal stem/pro­
genitor cells may share this property of lineage switching.
Among lineage­specific mechanisms, some trans  crip­
tion  factors  are  of  particular  significance  in  pancreatic 
lineage development, for example, Pdx1, Neurogenin 3 
(NGN3), and others, while cytokine networks represent 
another level of endocrine regulation in stem cells, for 
example,  activin  A  ­  a  member  of  the  transforming 
growth  factor  (TGF)­β  superfamily  ­  inducts  beta  cell 
differentiation in hESC [2, 12, 13].
To generate further insights into fetal human endocrine 
stem/progenitor cells, we isolated epithelial cells charac­
terized by the display of epithelial cell adhesion molecule 
(EpCAM), and studied mechanisms of proliferation and 
differentiation. This led us to define phenotypic changes 
in  cells  during  culture,  including  after  increased  cell 
replication with hTERT expression. We found that the 
initial  epithelial/endodermal  phenotype  of  fetal 
endocrine cells was altered with gain of mesenchymal/
mesodermal phenotype, which was similar to changes in 
stem/progenitor  cells  isolated  from  fetal  human  livers, 
further  emphasizing  sharing  of  mechanisms  in  cells 
originating from the foregut endoderm [9]. The ability to 
control the phenotype of these cells through additional 
manipulations  offers  potential  ways  to  regulate  cell 
differentiation  for  superior  β  cell  functions  and  to 
understand  mechanisms  in  stage­specific  β  lineage 
advancement in other types of stem/progenitor cells.
Materials and methods
Human tissues
Fetal tissues of 17 to 24 week gestation were from Human 
Fetal  Tissue  Repository  of  Albert  Einstein  College  of 
Medicine (Bronx, NY, USA). A total of 20 fetal pancreata 
were  used.  Mature  pancreatic  islets  were  from  Islet 
Distribution  Program  of  Juvenile  Diabetes  Research 
Foundation  New  York,  NY,  USA.  Procedures  for  fetal 
tissue collection, including informed consent in writing 
from donors, as well as this research were approved by 
the  Committee  on  Clinical  Investigations  (Institutional 
Review Board) at Einstein.
Cell isolation and culture
Fetal pancreases were rinsed in Leffert’s buffer (10 mM 
HEPES, 3 mM KCl, 130 mM NaCl, 1 mM NaH2PO4 and 
10  mM  glucose,  pH  7.4)  with  5  mM  CaCl2,  100  U/ml 
DNase (Worthington Biochemical Corp., Lakewood, NJ, 
USA), and 0.03% collagenase P (Roche Applied Science, 
Indianapolis,  IN,  USA).  Tissue  was  repeatedly  passed 
through 5 ml syringe and gently agitated in this buffer for 
20 to 30 minutes at 37°C. Dissociated cells were passed 
through 80 μm dacron (Sefar Filtration Inc. Depew, NY, 
USA)  and  washed  twice  in  phosphate  buffered  saline 
(PBS,  pH  7.2),  2  mM  EDTA,  0.5%  BSA  (wash  buffer) 
under 800 x g for five minutes at 4°C. After resuspending 
5x107 cells in 0.3 ml wash buffer, FcR blocking reagent 
was added, and cells were incubated with 100 μl micro­
beads conjugated with antibody against human EpCAM 
(Miltenyi Biotec Inc, Bergisch Gladbach, Germany) for 
30 minutes at 4°C. To verify cell separation, aliquots were 
incubated with FITC­conjugated anti­EpCAM (Miltenyi 
Biotec)  for  10  minutes  at  room  temperature  and 
examined  under  epifluorescence.  Remaining  cells  were 
resuspended  in  1  ml  PBS  with  pelleting  of  EpCAM­
positive  and  ­negative  fractions  in  wash  buffer  under 
300 x g for 10 minutes. Cell viability was determined by 
exclusion of 0.2% trypan blue dye.
For culture, 4x103 cells were plated in 35 mm dishes in 
Dulbecco’s Minimal Eagle Medium (DMEM) (Life Tech­
nologies Inc., Rockville, MD, USA) with 2.5 mM glucose, 
100 U/ml penicillin, 100 μg/ml streptomycin, 250 ng/ml 
amphotericin  B,  and  10%  fetal  bovine  serum  (FBS, 
Atlanta Biologicals Inc., Norcross, GA, USA) in 5% CO2 
at  37°C.  The  medium  was  replaced  twice  weekly  and 
near­confluent cells were subpassaged 1:3 with trypsin­
EDTA for three minutes at 37°C. We analyzed primary 
cells after short­term (1 to 2 d) or long­term (10 to 14 d) 
culture, followed by serial passages until cell replication 
declined. Cells expressing hTERT were cultured for >50 
passages.  Changes  in  cell  population  doublings  were 
determined  during  culture  by  manual  counting  of  cell 
numbers.  To  induce  insulin  expression,  cells  were 
cultured in serum­free medium for seven days and with 
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Minneapolis, MN, USA) for another three days.
hTERT retrovirus
The  vector  encoding  hTERT  and  puromycin  selection 
marker was previously described [10]. EpCAM­positive 
cells were transduced with 2 to 4 x 104 units/ml of hTERT 
retrovirus. Fresh DMEM was added after 24 h and cells 
were cultured to 70­80% confluency before adding 0.75 
μM puromycin (Sigma Biochemical Co., St. Louis, MO, 
USA). A clone of EpCAM­positive cells transduced with 
hTERT was designated hTERT­FPC.
Pdx1 lentivirus vector (LV)
The  pONY4­Pdx1  plasmid  containing  rat  Pdx1  cDNA 
was provided by Dr. S. Efrat (Tel Aviv University, Tel Aviv, 
Israel). Pdx1 cDNA was excised by BamHI and SalI and 
850 base pair fragment was subcloned into pCCLsinPPT.
hPGK.IRES.GFP.Wpre plasmid to obtain transfer plasmid 
designated pCCLsinPPT.hPGK.Pdx1.IRES.GFP.Wpre Pdx1­
LV was produced by calcium phosphate transfec  tion of 
293T cells as described [14]. pMDLg/pRRE was the HIV­
derived  packaging  construct,  pRSV­Rev  construct 
expressed Rev regulatory protein and pMD2.G construct 
expressed VSV­G envelope protein. To obtain high­titer 
LV, 293T medium was concentrated under 50,000 x g for 
140  minutes  with  tittering  of  LV  in  HeLa  cells.  To 
transduce cells, LV under 10 multiplicities of infection 
(MOI) was added to cells overnight at 37°C. Cell trans­
duction was analyzed after 72 h with flow cytometry for 
green fluorescent protein (GFP).
Cytostainings
A total of 4 x 103 cells were cultured on glass cover slips 
and fixed in cold ethanol for 10 minutes. Histochemical 
staining for glycogen, dipeptidyl peptidase IV (DPPIV) 
and γ­glutamyl transpeptidase (GGT) was as previously 
described [9]. For immunostaining, cells were fixed in 4% 
paraformaldehyde, blocked in goat or donkey serum with 
0.1% Triton X­100 in PBS for 10 minutes, and incubated 
for  one  hour  with  antibodies  at  room  temperature 
(Table  1).  To  measure  intensity  of  immunostaining, 
microphotographs were analyzed with ImageJ software 
(NIH, Bethesda, MD, USA).
Insulin radioimmunoassay
Cells were lysed for measuring insulin and c­peptide as 
previously  described  [4].  Data  were  normalized  to  cell 
numbers.
Reverse-transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted with Trizol Reagent (Invitrogen 
Life Technologies, Carlsbad, CA, USA). After incubation 
with  Amplification  Grade  DNase  I  (Invitrogen),  RNAs 
were  reverse  transcribed  with  Omniscript  RT  system 
(Qiagen  Inc.,  Valencia,  CA,  USA).  Equal  amounts  of 
cDNAs  were  amplified  with  Platinum  PCR  Supermix 
(Invitrogen) as follows: 94°C x 5 minutes and 35 cycles at 
94°C  x  30  sec,  annealing  at  various  temperatures  for 
30 sec, and 72°C for one minute, with final extension at 
72°C for seven minutes. PCR products were resolved in 
1.5% agarose containing ethidium bromide. Oligo  nucleo­
tide primers, annealing conditions and expected product 
sizes are listed in Table 2, including previously published 
conditions [9­11, 15­17].
Cell transplantation studies
The Animal Care and Use Committee of Albert Einstein 
College of Medicine approved animal use in conformity 
with National Research Council’s Guide for the Care and 
Use of Laboratory Animals (United States Public Health 
Service  publication,  revised  1996).  All  animals  were 
maintained in the Institute of Animal Studies at Albert 
Einstein College of Medicine. We transplanted 2 x 106 
hTERT­FPC modified by Pdx1 LV in NOD­CB17­prkdc­
SCID mice (Jackson Labs., Bar Harbor, ME, USA) into 
portal vein as described previously [18]. Animals were 
sacrificed in groups (n = 3 each) 24 hours and one, two or 
four weeks after transplantation to analyze cell engraft­
ment and gene expression. To verify presence of trans­
planted cells in the liver, genomic DNA was isolated by 
Trizol  Reagent.  A  primate­specific  sequence  from  the 
Charcot­Marie­Tooth (CMT)­1A element was amplified 
by PCR and in situ hybridization was performed with a 
Table 1. Immunostaining protocols
Antigen  Blocking  Primary Antibody  Dilution  Secondary Antibody  Dilution
Insulin  3% Goat serum  AB3440, Guinea Pig anti-human insulin   1:100  Rhodamine-conjugated anti-guinea pig IgG  1:500 
    (Chemicon El Segundo, CA)    (AB7136, Abcam, Cambridge, MA)
Glucagon  3% Goat serum  AB932, Rabbit anti-Glucagon   1:100  Goat anti-Rabbit IgG, Cy3-conjugated  1:500 
    (Chemicon El Segundo, CA)     (AP132C, Chemicon)
C-peptide  3% Goat serum  ab14181, Rabbit anti-c-peptide   1:100  Goat anti-Rabbit IgG, Cy3-conjugated  1:500 
    (Abcam Inc, Cambridge, MA)     (AP132C, Chemicon)
Vimentin  5% Donkey serum  V212210,   1:100  Rhodamine-conjugated antimouse IgG  1:500 
    (United States Biologicals, Swampscott, MA)     (#715-295-150, Jackson Immuno Research)
IgG, Immunoglobulin G.
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Gene  Primer sequences (5’-3’): Forward and Reverse  Tm (°C)  Product (basepairs)  References
Insulin  GCTGCATCAGAAGAGGCCATCAGGC  58  380  [11] 
  GCGTCTAGTTGCAGTAGTTCTCCAG
Glucagon  GAATTCATTGCTTGGCTGGTGAAAGGC  60  255  [11] 
  CATTTCAAACATCCCACGTGGCATGCA
Pancreatic Polypeptide   CTGCTGCTGCTGTCCACCTGCGTG  60  206  [11] 
  CTCCGAGAAGGCCAGCGTGTCCTC
Somatostatin  CGTCAGTTTCTGCAGAAGTCCCTGGCT  60  206  [11] 
  CCATAGCCGGGTTTGAGTTAGCAGATC
NeuroD  ATCCCAACCCACCACCAACC  60  440  [15] 
  CAGCGGTGCCTGAGAAGATT
Pancreatic duodenal homeobox1 gene (Pdx1)  CTGCCTTTCCCATGGATGAA  58  277  [15] 
  CGCTTCTTGTCCTCCTCCTTT
Prohormone convertase (PC1/3)  TTGGCTGAAAGAGAACGGGATACATCT  65  456  [11] 
  ACTTCTTTGGTCATTGCTTTGGCGGTG
Prohormone convertase (PC2)  GCATCAAGCACAGACCTACACTGG  60  308  [11] 
  GAGACACAAACCACCCTTCATCCTTC
Chromogranin-A   CGGACAGTTCCATGAAGCTCTC  58  444  [11] 
  GAGTCAGGAGTAGGAGACAAGG
Glucokinase   GACGAGTTCCTGCTGGAGTATGAC  65  523  [11] 
  GACTCGATGAAGGTGATCTCGCAGCTG
Paired homeobox gene4 (PAX4)  CACCTCTCTGCCTGAGGACACGGTGAG  64  443  [11] 
  CTGCCTCATTCCAAGCCATACAGTAGTG
Paired homeobox gene 6 (PAX6)  CAGTCACAGCGGAGTGAATCAGC  58  519  [11] 
  GCCATCTTGCGTAGGTTGCCCTG
Glucose transporter2 (GLUT2)  GCCATCCTTCAGTCTCTGCTACTC  65  523  [11] 
  GCTATCATGCTCACATAACTCATCCA
Betacellulin2 (BETA2)  CCTGAGCAGAACCAGGACATGCC  58  221  [11] 
  ATCAAAGGAAGGGCTGGTGCAATCA
Neurogenin3 (NGN3)  ACTGAGCAAGCAGCGACGGAGTC  65  448  [11] 
  GCACCCACAGCCGAGCGACAGAC
NK homeobox protein 6.1 (NKX6 1)  CTCCTCCTCGTCCTCGTCGTCGTC  60  699  [11] 
  CTTGACCTGACTCTCTGTCATC
NK homeobox protein 2.2 (NKX2 2)  CGGACAATGACAAGGAGACCCCG  65  490  [11] 
  CGCTCACCAAGTCCACTGCTGCTGG
Islet1 (ISL1)  GTGCGGAGTGTAATCAGTATTTGG  58  519  [11] 
  GTCATCTCTACCAGTTGCTCCTTC
GATA2 transcription factor  CGTCTTCTTCAATCACCTCG  55  225  [10] 
  CGTCTTGGAGAAGGGGCTC
GATA6 transcription factor  GAAGAAGCACATGATTTTGGAC  58  181  [10] 
  GATGGAAGGGAAGGGCCAG
Transforming growth factor alpha (TGFα)  ATGGTCCCCTCGGCTGGA  58  297  [10] 
  GGCCTGCTTCTTCTGGCTGGCA
Transforming growth factor beta1 (TGFβ1)  GCCCTGGACACCAACTATTGCT  58  161  [10] 
  AGGCTCCAAATGTAGGGGCAGG
Transforming growth factor beta2 (TGFβ2)  GATTTCCATCTACAAGACCACGAGGGACTTGC  65  503  [10] 
  CAGCATCAGTTACATCGAAGGAGAGCCATTCG
Transforming growth factor beta1 receptor (TGFβ1R)  CGTGCTGACATCTATGCAAT  54  251  [10] 
  AGCTGCTCCATTGGCATAC
Transforming growth factor beta2 receptor (TGFβ2R)   TGCACATCGTCCTGTGGAC  58  784  [10] 
  GTCTCAAACTGCTCTGAAGTGTTC
Insulin-like growth factor receptor (IGFR)   ACCCGGAGTACTTCAGCGCT  55  229  [10] 
  CACAGAAGCTTCGTTGAGAA
Cytokeratin-19  ATGGCCGAGCAGAACCGGAA  60  308  [16] 
  CCATGAGCCGCTGGTACTCC
α-Smooth muscle actin   AGTACCCGATAGAACATGG  60  153  [9] 
  TTTTCTCCCGGTTGGC
Vimentin  CACCTACAGCCTCTACG  60  170  [9] 
  AGCGGTCATTCAGCTC
Human telomerase reverse transcriptase (hTERT)  AAGTTCCTGCACTGGCTGATGAG  60  378  [17] 
  TCGTAGTTGAGCACGCTGAACAG
β-actin  AGAGCTATGAGCTGCCTGAC  55  361  [15] 
  CTGATCCACATCTGCTGGAA
Glyceraldehyde phosphate dehydrogenase (GAPDH)  CCATGGAGAAGGCTGGGG  58  194  [10] 
  CAAAGTTGTCATGGATGACC
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cribed  [19].  GFP  immunostaining  was  performed  as 
described [18]. In some studies, tissues were additionally 
stained  for  insulin  as  described  above.  After  washing 
with  PBS,  tissues  were  counterstained  with  DAPI 
(4’ ,6­diamidino­2­phenylindole)­antifade  (Molecular  Probes, 
Invitrogen Life Technologies Corporation, Carlsbad, CA, 
USA) and examined under epifluorescence.
Statistical analysis
Data are shown as means ± SD. Significances were exam­
ined by t­test. P values <0.05 were considered significant.
Results
Characterization of pancreatic epithelial cells
After  immunomagnetic  sorting,  we  obtained  1­3  x  107 
EpCAM­positive epithelial cells per fetal pancreas with 
viability  of  85  to  90%.  Intact  fetal  pancreas  showed 
primitive acini, as well as islets with ductal and vascular 
structures  (Figure  1a).  Cells  in  ductal,  periductal  and 
acinar regions expressed the ductal markers, DPPIV and 
GGT. EpCAM staining verified the presence of epithelial 
cells  with  DPPIV  and  GGT  expression  in  those  areas. 
Similarly,  EpCAM­positive  isolated  cells  expressed 
DPPIV and GGT, whereas cells with glycogen, which is a 
characteristic of pancreatic acinar cells and not beta cells, 
were  not  observed  in  this  fraction  (Figure  1b).  By 
contrast, the EpCAM­negative cell fraction showed only 
infrequent  EpCAM,  DPPIV  or  GGT­positive  cells, 
whereas cells with glycogen were frequent (Figure 1c).
Cells in the EpCAM­positive fraction expressed insulin 
or glucagon, often both, whereas in the EpCAM­negative 
fraction, cells expressing insulin or glucagon were rare 
(Figure 2). Taken together, these findings indicated that 
EpCAM  selected  epithelial  cells  and  that  endocrine 
progenitor cells were present within epithelial cell niches 
in the fetal pancreas.
After  culture,  differences  in  EpCAM­positive  and  –
negative fractions were apparent, as the former retained 
epithelial morphology, whereas the latter showed spindle­
shaped morphology (Figure 3a and 3b). In primary (P0) 
culture, EpCAM­positive cells proliferated within several 
days  to  form  confluent  monolayers  of  cells,  although 
replication of cells declined over 10 to 12 passages, and 
cells required greater times to form confluent cultures. It 
was noteworthy that cells continued to express EpCAM, 
as  shown  by  immunostaining,  which  simultaneously 
verified  the  absence  of  nonepithelial  cells  in  cultures. 
Also,  EpCAM­positive  cells  expressed  pancreatic 
polypeptide (PP), somatostatin, glucagon and insulin in 
short­term culture (1 to 2 d), whereas after longer­term 
culture (10­14 d), PP was no longer expressed (Figure 3C). 
By contrast, in EpCAM­negative cells, insulin, glucagon 
and somatostatin were expressed at lower levels and only 
Figure 1. Fractionation of EpCAM-positive epithelial cells from fetal human pancreas. (a) shows intact 22-week fetal human pancreas with 
hematoxylin staining alone (extreme left) or histochemical staining for DPPIV, GGT and glycogen, as indicated, which were expressed in cells 
in ductal (arrows), periductal and acinar regions. (b) shows EpCAM-positive cells isolated by immunomagnetic cell sorting with EpCAM, DPPIV 
and GGT expression but absence of glycogen. (c) shows EpCAM-negative cell fraction with only occasional epithelial cells and more abundant 
glycogen-containing acinar cells (arrows, panel extreme right). Orig. mag., a, x200; b and c, x400.
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was  expressed  in  EpCAM­positive  cells  in  short­  and 
long­term  cultures.  BETA2  and  NeuroD  transcription 
factors, which regulate β­cell differentiation, were expressed 
in EpCAM­positive cells, as were transcriptional regula­
tors,  GATA­2,  GATA­4  and  GATA­6,  which  govern 
differentiation of additional mesodermal lineages. NGN3 
was expressed in EpCAM­positive cells. Other regulatory 
transcription factors, for example, Pax­4, Pax­6, Nkx­2.2 
and  Nkx­6.1,  were  either  not  expressed,  or  were 
expressed  less  well  in  EpCAM­positive  cells,  although 
Isl­1,  which  promotes  islet  cell  development,  was 
expressed  during  short­term  cell  culture.  The  glucose 
trans  porter,  GLUT­2,  and  glucokinase  (GK),  which 
partici  pate in signal­secretion coupling in β­cells, were 
expressed  in  only  EpCAM­positive  cells.  These  cells 
expressed  proinsulin  processing  enzymes,  prohormone 
convertases,  PC1/3  and  PC2,  and  chromogranin  A 
(CGA),  the  major  component  of  dense­core  secretory 
granules. Finally, growth factor genes regulating islet and 
β­cell development, for example, TGF­α, TGF­β1, TGF­
β2,  and  their  receptors,  as  well  as  insulin­like  growth 
factor­1 receptor (IGF­1R), were expressed.
Proliferation of EpCAM-positive cells after telomerase 
reconstitution
In  mature  pancreatic  islets  or  in  fetal  pancreas,  hTERT 
mRNA was absent (Figure 4a). After hTERT introduction, 
RT­PCR  showed  hTERT  mRNA  in  transduced  cells, 
similar to hTERT­FH­B fetal human liver cells [10]. Serial 
cultures of hTERT­FPC demonstrated robust prolifera  tion 
despite  >50  passages,  during  which  >170  estimated  cell 
population  doublings  occurred,  which  was  beyond  the 
boun  daries  of  replicative  senescence  in  somatic  cells. 
Comparison  of  cell  doubling  rates  showed  proliferation 
was  significantly  increased  in  FPC  after  expression  of 
hTERT  (Figure  4b).  The  human  identity  of  hTERT­FPC 
was verified by PCR of DNA with human­specific CMT­1A 
probe, as well as in situ hybridization for primate­specific 
alphoid satellite sequences in centro  meres [19]. Morpho­
logically, hTERT­FPC resembled unmanipulated primary 
EpCAM­positive fetal cells. To address whether hTERT­
FPC  maintained  endocrine  functions,  we  deter  mined 
insulin  expression  (Figure  4c).  Primary  EpCAM­positive 
fetal cells expressed insulin during culture over up to two 
weeks and insulin was expressed in cultured hTERT­FPC 
after  up  to  four  passages  (P4).  Subsequently,  insulin 
expression declined in hTERT­FPC, and was undetectable 
after  10  passages.  This  was  asso  ciated  with  a  parallel 
decline, and eventual loss, of Pdx1 expres  sion in hTERT­
FPC, indicating that the β­cell pheno  type of hTERT­FPC 
was perturbed during cell culture.
Restoration of endocrine phenotype in hTERT-FPC
We  studied  whether  restoring  Pdx1  expression  will 
reconstitute  the  endocrine  phenotype  of  hTERT­FPC. 
Figure 2. Endocrine phenotype of EpCAM-positive fetal pancreatic cells. (a) shows immunostaining of 22-week fetal human pancreas to 
demonstrate cells in primitive pancreatic islets with coexpression of insulin and glucagon. Negative controls, where primary antibodies were 
omitted, are on extreme right. (b) shows isolated freshly EpCAM-positive cells with coexpression of insulin and glucagon in some cells. (c) shows 
EpCAM-negative fraction showing occasional cells with glucagon. Orig. mag., a, x200; b and c, x400.
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morphology of EpCAM-positive cells. (c) shows RT-PCR for genes as indicated. Lanes 1 to 6 show results from mature human pancreatic islets, 
intact fetal pancreas, cells after early term culture (1 to 2 d) or longer culture (10 to 14 d). For comparisons, β-actin and glyceraldehyde phosphate 
dehydrogenase (GAPDH) genes were included.
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Page 7 of 13Therefore, we expressed rat Pdx1 and green fluorescent 
protein  (GFP)  under  phosphogylcerate  kinase  (PGK) 
promoter, which is ubiquitously active (Figure 5a). After 
transduction  of  hTERT­FPC  with  Pdx1  LV  >90%  cells 
were  GFP­positive  (Figure  5b  and  5c).  GFP  expression 
was  maintained  over  multiple  cell  passages.  Rat  Pdx1 
induced  glucagon  and  ISL1  expression  in  hTERT­FPC, 
without  expression  of  endogenous  hPdx1  or  insulin 
under  basal  conditions  (Figure  5d).  However,  when 
hTERT­FPC were cultured in serum­free medium with 
activin A, hPdx1 and insulin mRNA were expressed and 
hTERT­FPC­Pdx1  also  contained  immunostainable 
insulin  and  c­peptide.  Neither  hPdx1  nor  insulin  was 
detected in hTERT­FPC without transduction with Pdx1 
LV. No insulin was detected by immunoassay in un  differ­
entiated  hTERT­FPC,  whereas  hTERT­FPC­Pdx1  cells 
cultured  without  serum  and  with  activin  A  contained 
5 ± 3 ng insulin per 1 x 106 cells. This indicated that Pdx1 
restored endocrine progenitor phenotype in hTERT­FPC, 
although  activin  A  was  required.  Detailed  studies  of 
regulated insulin secretion were not attempted in view of 
relatively limited insulin expression in hTERT­FPC­Pdx1 
cells and requirement of further differentiation in cells.
Endodermal-mesenchymal phenotype conversions
To  examine  the  phenotype­regulating  mechanism  of 
activin  A,  we  determined  whether  hTERT­FPC  transi­
tioned  to  an  epithelial­mesenchymal  state,  which  was 
recently recognized in endodermal cells [9]. We found 
that EpCAM­positive fetal pancreatic cells expressed the 
intermediate  filament  characteristic  of  epithelial  cells, 
cytokeratin  (CK)­19,  with  minimal  expression  of  the 
mesenchymal filament, vimentin (Figure 6a). By contrast, 
in  Pdx1­LV­transduced  hTERT­FPC,  expression  of 
vimentin  increased,  while  CK­19  was  also  expressed, 
indicating  a  mixed  epithelial­mesenchymal  phenotype. 
After activin A, expression of vimentin declined without 
affecting  CK­19  expression.  It  was  noteworthy  that 
expression of TGF­β1, TGF­β2 and their receptors was 
unchanged.  This  was  associated  with  changes  in  cell 
morphology, such that cultured hTERT­FPC were larger 
and  flatter  in  the  presence  of  serum,  whereas  hTERT­
FPC­Pdx1  cells  became  smaller  and  rounder  when 
cultured without serum and in the presence of activin A 
(Figure 6b). Moreover, these morphological changes were 
accompanied by decreased expression of vimentin, which 
was verified by immunostaining of cultured cells (Figure 6c).
Transplantation of hTERT-FPC cells in NOD/SCID mice
The  fate  of  hTERT­FPC  was  established  in  vivo  by 
transplantation  studies  in  mice.  Transplanted  hTERT­
FPC were present in the liver throughout the four­week 
period  of  studies  (Figure  7a).  Transplanted  cells  were 
localized in the liver by in situ hybridization (Figure 7b 
and 7f). Moreover, presence of GFP expression, as well as 
simultaneous  expression  of  insulin  in  GFP­positive 
hTERT­FPC  that  had  been  modified  by  Pdx1­LV  was 
observed (Figure 7g and 7i). No tumors were detected in 
animals  after  cell  transplantation  over  the  four­week 
period of the study.
Discussion
We successfully isolated epithelial progenitor cells from 
the fetal human pancreas and isolated cells were greatly 
Figure 4. Immortalization of EpCAM-positive fetal pancreatic 
cells by hTERT. (a) shows RT-PCR for hTERT expression after early and 
late passages of hTERT-FPC. Note the absence of hTERT expression 
in mature human islets and fetal pancreas, whereas hTERT-FH-B 
fetal human liver cells expressed hTERT (positive control). (b) shows 
kinetics of proliferation in primary EpCAM-positive fetal pancreatic 
cells and hTERT-FPC during culture over up to four weeks, which 
was 4-6-fold greater in the latter. Asterisks indicate P <0.05. (c) shows 
RT-PCR for insulin, which was expressed in mature islets (lane 1), 
fetal pancreas (lane 2) and primary EpCAM-positive cells during early 
and late culture (lanes 3 and 4), as well as an early passage (P3) of 
hTERT-FPC (lane 5) but not in hTERT-FPC after further cell culture 
(lane 6).
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Page 8 of 13expanded after genetic modification with hTERT in vitro. 
These  cells  exhibited  endocrine  progenitor  phenotype 
with multiple pancreatic hormones, although this pheno­
type was altered in culture conditions with acquisition of 
additional mesenchymal/mesodermal properties. As this 
phenotype  change  occurred  through  spontaneous  pro­
cesses,  we  believe  the  availability  of  hTERT­modified 
pan  creatic  cells  will  offer  additional  substrates  for 
dissect  ing regulatory mechanisms in beta cell differen­
tiation. In particular, our findings should be of interest in 
determining  whether  other  stem/progenitor  cells  will 
transition through similar fetal stages during generation 
of β or beta­like cells.
During development, pancreatic progenitor cells arise 
from the primitive foregut endoderm, with cell­specifi­
cation requiring Pdx1 and other transcription factors, for 
Figure 5. Induction of insulin-expression in hTERT-FPC by Pdx1-LV. (a) shows schematic of LV with rat Pdx1 and GFP genes driven by hPGK 
promoter – IRES, intervening internal ribosomal entry site, cPPT, central polypurine tract, Wpre, posttranscriptional regulatory element of the 
woodchuck hepadnavirus. (b) shows Pdx1-LV-transduced hTERT-FPC under phase contrast (top) and under epifluorescence for GFP. (c) shows 
flow cytometric quantitation of GFP in nontransduced cells (top panel) and Pdx1-LV-transduced hTERT-FPC. MFI = mean fluorescence intensity. 
(d) shows RT-PCR for gene expression in control hTERT-FPC (lane 1), Pdx1-LV-transduced hTERT-FPC cultured without serum (lane 2) and without 
serum plus activin A (lane 3), and mature pancreatic islets (lane 4). (e) shows insulin and c-peptide expression in negative control hTERT-FPC-Pdx1 
cells, where primary antibodies were omitted, and cells with expression of both insulin and c-peptide. Orig. Mag., x 200.
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Page 9 of 13example,  HNF  homeobox  B,  NGN3,  pancreas­specific 
transcription factor 1a, GATA4, and HNF6 [12]. We were 
able  to  isolate  pancreatic  epithelial  progenitor  cells 
characterized  by  the  epithelial­specific  adhesion 
molecule,  EpCAM,  which  is  a  feature  of  endodermal 
stem/progenitor  cells  [8,  9],  although  these  cells 
demonstrated  limited  proliferation  capacity  in  culture 
conditions. The replication potential of fetal human liver 
stem/progenitor  cells  expressing  EpCAM  was  similarly 
limited  and  was  accompanied  by  telomere  shortening, 
which could be circumvented by hTERT expression [10]. 
In the same way, modification of pancreatic progenitor 
cells  with  hTERT  greatly  expanded  their  capacity  to 
proliferate. The ability of other somatic cells, and even 
iPS cells, to assume greater proliferation capacity after 
modification with hTERT has been established [6, 10]. 
This role of hTERT should be noteworthy because of the 
absence of tumorigenicity in hTERT­modified cells [10, 
20],  as  shown  previously,  and  again  in  our  cell  trans­
plantation studies here, where transplanted cells did not 
generate foci of proliferating cells and no tumors were 
observed over at least four weeks.
We do not propose that genetically­modified cells with 
hTERT  expression  will  be  appropriate  for  immediate 
clinical applications, as more information will be needed 
in  regards  to  their  biological  properties,  regulation  of 
differentiation through nonintegrating vectors in case of 
gene  therapy­type  approaches  or  of  alternative  small 
molecule  approaches  for  this  purpose,  as  recently 
identified during β lineage derivation in hESC [21]. The 
availability  of  fetal  cells  described  here  will  permit 
comparative  studies  of  differentiation  mechanisms  in 
pluripotent stem cells versus stem/progenitor cells with 
specific  lineage  commitment.  Our  preliminary  studies 
indicated that (­)­indolactam V, which was effective for 
inducing beta cell maturation in hESC­derived cells [21], 
failed  to  enhance  beta  cell  phenotype  in  hTERT­FPC, 
suggesting fundamental differences in regulation of beta 
cell  differentiation  in  various  types  of  stem/progenitor 
cells.
The loss of insulin expression in cultured FPC was in 
agreement  with  previous  studies,  for  example,  down­
regulation  of  hormone  expression  was  a  feature  of 
immorta  lized human pancreatic cell lines, as well as of 
growth­stimulated primary human pancreatic cells [22, 
23].  Whether  loss  of  gene  expression  was  due  to 
transcriptional  downregulation,  independent  of  cell 
differentiation, or switching of progenitor cells to more 
primitive states, were both possibilities. In our studies, 
EpCAM­positive fetal epithelial cells displayed properties 
of  islet  progenitor  cells  with  expression  of  multiple 
hormones and relevant transcription factors in early cell 
culture  conditions.  We  found  that  loss  of  insulin 
expression was coupled with simultaneous loss of Pdx1 
expression in hTERT­FPC. Subsequently, we found that 
although  this  initial  epithelial/endodermal  phenotype 
Figure 6. Phenotype alterations in fetal pancreatic cells. (a) shows RT-PCR for epithelial marker, CK-19, and mesenchymal marker, vimentin, 
along with TGF-β1, TGFβ2 and their receptors under various conditions indicated. (b) shows morphological changes in LV-Pdx1-transduced 
hTERT-FPC during culture with serum and in the absence of serum plus addition of Activin A (bottom panel). These data indicated that cells became 
more rounded and less flattened in the absence of serum and presence of Activin A. (c) shows changes in vimentin expression by immunostaining 
in LV-Pdx1-transduced hTERT-FPC cultured with serum (top left), and with Activin A and no serum (bottom left). No immunostaining was detected 
when vimentin antibody was omitted (top right). The panel at bottom right in c shows quantitation of vimentin immunofluorescence signals by 
image analysis to indicate that culture without serum and with activin A perturbed cell phenotype, which was in agreement with morphological 
changes in LV-Pdx1-transduced hTERT-FPC.
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Page 10 of 13was  maintained  in  cells,  additional  properties  typically 
encountered  in  mesenchymal/mesodermal  cells,  for 
example, vimentin expression, were displayed. This was 
strongly reminiscent of changes in EpCAM­positive fetal 
human liver stem/progenitor cells, where downregulation 
of the epithelial/endodermal phenotype was due to the 
onset of conjoint meso­endoderm (epithelial plus mesen­
chymal)  phenotype  under  culture  conditions  [9].  Also, 
these  fetal  human  liver  cells  regained  expression  of 
epithelial  genes  after  culture  under  serum­free  condi­
tions, which strengthened sharing of mechanisms observed 
in fetal pancreatic cells here.
Therefore, our findings of increased insulin expression 
in  hTERT­FPC  following  culture  under  serum­free 
conditions with activin A were in agreement with the role 
of pathway­specific soluble signals in cell differentiation. 
The role of activin A in enhancing insulin expression in 
hTERT­FPC resembled the role of inductive signaling in 
generating β­like cells from hESC [13], and of extrinsic 
signaling  in  inducing  hepatic  properties  in  fetal  stem/
progenitor cells [9]. These shared mechanisms will offer 
new opportunities for exploring genetic and epigenetic 
processes  in  pancreatic  lineage  regulation,  including 
induction of the beta cell phenotype. The availability of 
hTERT­FPC  and  hTERT­FH­B  cells  derived  from  fetal 
liver and pancreas, respectively, should provide impor­
tant opportunities for comparing hESC­ or iPS­derived 
cells in understanding transitions of embryonic­to­fetal 
and fetal­to­adult stages in the β cell lineage. For instance, 
it  should  be  relevant  to  determine  whether  candidate 
Figure 7. Transplantation studies with hTERT-FPC. (a) shows DNA PCR for human sequences to identify hTERT-FPC in the liver of NOD/SCID 
mice 24 hours, 1 week, 2 weeks and 1 month after intrasplenic transplantation. (b-f) show in situ hybridization for alphoid satellite sequences in 
human centromeres to verify that transplanted cells were present in tissues. (b), fetal human liver as positive control to show hybridization signals in 
cell nuclei (arrow); (c), mouse liver showing absence of hybridization signals; (d), (e) and (f) show tissues from animals 24 hours, 1 week and 1 month 
after cell transplantation, respectively, with transplanted cells localized by nuclear in situ signals (arrows). (g-i) show sequential immunostaining 
for GFP (g) and insulin (h) with merged image of these two panels (i) two weeks after transplantation in the liver to verify β cell phenotype in 
transplanted hTERT-FPC.
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Page 11 of 13approaches  capable  of  advancing  β  cell  maturation  in 
hESC­derived cells, could be equally effective in hTERT­
FPC or hTERT­FH­B cells.
As hTERT­FPC were capable of expressing insulin in 
vivo,  this  was  similar  to  the  expression  of  hepatic 
functions in fetal human liver epithelial cells following 
transplantation in xenotolerant mice [9]. In other studies, 
transplantation of hTERT­FH­B fetal liver cells modified 
by Pdx1, was successful in correcting hyperglycemia in 
mice [11, 24]. Here, our cell transplantation studies were 
limited to establishing differentiation of hTERT­FPC in 
the liver. Whether these cells could correct hyperglycemia 
in  animals  will  require  detailed  studies  in  the  future, 
particularly after further differentiation and maturation 
of cells along the β lineage.
Conclusions
Insights  into  lineage­switching  mechanisms  during 
expan  sion  of  pancreatic  stem/progenitor  cells  will  be 
critical  for  understanding  the  fundamental  nature  of 
expanded  cells.  The  availability  of  hTERT­FPC  should 
facilitate  efforts  to  identify  effective  mechanisms  to 
maintain stem/progenitor cells under suitable states for 
cell  expansion  without  extinction  of  differentiation 
capacity. This will be useful for translational applications, 
including cell therapy in type­1 diabetes mellitus.
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